Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD6750 · 1 trial · 9 indications
To assess the safety and tolerability, characterize the DLTs, and determine the MTD and RP2D(s) of AZD6750 as a single agent and in combination with other anti-cancer agents as specified in each respective module
To assess the preliminary anti-tumor activity of AZD6750 in combination with other anti-cancer agents.
| Arm | Type | Description |
|---|---|---|
| Module 1 | EXPERIMENTAL | AZD6750 administered intravenously (IV) as a single agent |
| Module 2 | EXPERIMENTAL | AZD6750 given in combination with rilvegostomig (IV) |
| Name | Type | Description |
|---|---|---|
| AZD6750 | DRUG | AZD6750- CD8 guided IL-2 |
| rilvegostomig | DRUG | Rilvegostomig- PD1-TIGIT bispecific antibody |
Inclusion criteria: * Participant ≥ 18 year * ECOG PS of 0 to 1 * Provision of 'archival' tumor specimen * At least one measurable lesion according to RECIST v1.1, * Minimum life expectancy of 12 weeks * Adequate and stable cardiac function * Adequate bone marrow, liver and kidney function * Body w...
Top 20 of 51 competitors
AZD6750 is an investigational small molecule being developed for the treatment of melanoma and other advanced or metastatic solid tumors. It is currently being studied in adult participants with conditions including non-small cell lung cancer, squamous cell carcinoma of the skin, renal cell carcinoma, Merkel cell carcinoma, triple negative breast cancer, head and neck squamous cell carcinoma, gastric cancer, and high grade serous ovarian carcinoma.
AZD6750 is being developed by AstraZeneca PLC, a biopharmaceutical company traded on the stock exchange under the ticker symbol AZN. The company is currently conducting clinical research on this investigational drug candidate.
AZD6750 is in Phase 1 clinical development. It is an investigational drug that has not been approved by regulatory authorities. The drug is currently being evaluated in an early-stage clinical trial to assess its safety in adult participants with select advanced or metastatic solid tumors.
AZD6750 is being studied in a Phase 1 clinical trial with the identifier NCT07115043. This trial is titled 'A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors' and is currently recruiting participants in the United States, Australia, Japan, and South Korea.
AZD6750 is a small molecule therapeutic agent. The specific molecular target of AZD6750 has not been disclosed in available information. The drug is being investigated for its potential to treat various types of cancer, including melanoma and other solid tumors.